DJ Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability
21-Jul-2021 / 07:05 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Aubagne, July 21, 2021
Information on Document Availability
The report on the first half 2021 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:
https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations
It contains the following information:
- Business development for the period of January to June 2021 as well as the 2021 full year forecast for the
Sartorius Stedim Biotech Group
- Consolidated financial statements for the period ended June 30, 2021
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions
provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own
manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies,
Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has
been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed
more than 7,500 people, and earned sales revenue of 1,910 million euros.
Contact
Petra Kirchhoff
Head of Corporate Communications
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
=----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file
File: Information on Document Availability
=----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: info@sartorius-stedim.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext DIM
Ticker:
AMF Category: Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly
financial report
EQS News ID: 1220485
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1220485 21-Jul-2021 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1220485&application_name=news
(END) Dow Jones Newswires
July 21, 2021 01:05 ET (05:05 GMT)
